GlaxoSmithKline Pakistan Ltd
Shariah compliantAlmost no debt, a strong business, the price in an uptrend and analysts seeing upside. No read is against it.
Working
- 1 analysts' average target Rs 510, 52% above the price.
- Debt is 1% of equity in the latest quarter.
- Revenue up 17% on the same quarter last year.
To watch
- Raised last year, from Rs 10.00 to Rs 17.00.
Keep reading GLAXO: business, price trend and value
How good the business is, where its support zone sits, what it may be worth, its health, dividends, peers and latest results open with a free account.
Latest results
Quarter: Jul–Sep 2026In the Jul–Sep 2026 quarter, GLAXO's sales rose 17% to Rs 16.6bn, from Rs 14.2bn, and profit after tax rose 28% to Rs 2.6bn, from Rs 2.0bn (compared with Jul–Sep 2025).
Earnings per share were Rs 8.20, against Rs 6.40 a year earlier.
At Rs 335.12, GLAXO trades at 10.4 times earnings, with a dividend yield of 5.7%.
- P/E ratio
- 10.4
- Dividend yield
- 5.7%
- Dividend payout
- 0%
- of earnings
- Return on equity
- 32%
- Net margin
- 16.0%
- last 12 months
- Debt to equity
- 0.01
GLAXO quarterly results
Reported figures| Quarter | Sales | Profit after tax | Net margin | EPS | Dividend / share |
|---|---|---|---|---|---|
| Jul–Sep 2026 | Rs 16.6bn | Rs 2.6bn | 15.7% | Rs 8.20 | — |
| Apr–Jun 2026 | Rs 14.5bn | Rs 2.0bn | 13.6% | Rs 6.19 | Rs 7.00 |
| Jan–Mar 2026 | Rs 17.0bn | Rs 2.6bn | 15.3% | Rs 8.20 | — |
| Oct–Dec 2025 | Rs 21.4bn | Rs 3.8bn | 17.7% | Rs 11.90 | Rs 12.00 |
| Jul–Sep 2025 | Rs 14.2bn | Rs 2.0bn | 14.4% | Rs 6.40 | — |
| Apr–Jun 2025 | Rs 14.7bn | Rs 2.1bn | 14.1% | Rs 6.50 | Rs 5.00 |
| Jan–Mar 2025 | Rs 15.6bn | Rs 2.1bn | 13.7% | Rs 6.68 | — |
| Oct–Dec 2024 | Rs 17.6bn | Rs 3.0bn | 16.8% | Rs 9.27 | Rs 10.00 |
GLAXO annual results and dividends
Reported figures| Year | Sales | Profit after tax | EPS | Dividend / share |
|---|---|---|---|---|
| Year to Dec 2025 | Rs 65.9bn | Rs 10.0bn | Rs 31.48 | Rs 17.00 |
| Year to Dec 2024 | Rs 61.2bn | Rs 6.5bn | Rs 20.52 | Rs 10.00 |
| Year to Dec 2023 | Rs 49.7bn | Rs 534.0mn | Rs 1.68 | — |
| Year to Dec 2022 | Rs 41.8bn | Rs 2.5bn | Rs 7.73 | — |
| Year to Dec 2021 | Rs 36.7bn | Rs 5.4bn | Rs 16.81 | Rs 7.00 |
Balance sheet and price
Balance sheet as of Sep 2026- Total assets
- Rs 53.8bn
- Shareholders' equity
- Rs 34.8bn
- Cash & bank
- Rs 8.1bn
- Total debt
- Rs 338.0mn
- Current ratio
- 2.20
- 3-month high
- Rs 360.14
- 3-month low
- Rs 300.07
- 1-month change
- +6.4%
- 3-month change
- -3.1%
Read more about GLAXO
Other pharmaceuticals companies
- ABOTAbbot Laboratories (Pakistan) LtdRs 924.15P/E 11.1
- AGPAGP LtdRs 149.85P/E 12.7
- BFBIOBF Biosciences LtdRs 123.20P/E 20.0
- CPHLCiti Pharma LtdRs 63.42P/E 15.7
- CWHCCrestwell Healthcare LimitedRs 21.35
- FEROZFerozsons Laboratories LtdRs 337.68P/E 16.4
- HALEONHaleon Pakistan LtdRs 658.64P/E 12.7
- HINOONHighnoon Laboratories LtdRs 956.76P/E 12.1
- HPLHoehcst Pakistan LtdRs 4056.91P/E 10.4
- IBLHLIBL HealthCare LtdRs 39.86P/E 19.1
- LIVENLiven Pharma LimitedRs 31.47
- MACTERMacter International LtdRs 244.00P/E 15.3
GLAXO: common questions
What is GLAXO's share price?
GlaxoSmithKline Pakistan Ltd (GLAXO) last closed at Rs 335.12 on the Pakistan Stock Exchange.
Does GLAXO pay a dividend?
Yes. GlaxoSmithKline Pakistan Ltd paid Rs 17.00 per share for the year to Dec 2025, and the stock's dividend yield is 5.7%.
What were GLAXO's latest results?
In the Jul–Sep 2026 quarter, GLAXO's sales rose 17% to Rs 16.6bn, from Rs 14.2bn, and profit after tax rose 28% to Rs 2.6bn, from Rs 2.0bn (compared with Jul–Sep 2025).
What is GLAXO's P/E ratio?
At Rs 335.12, GLAXO trades at 10.4 times its earnings.
Figures are taken from the company's published financial statements and PSX prices. This page is information, not investment advice.

